Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $20.3333.

ENTA has been the subject of several recent analyst reports. JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the stock from $14.00 to $20.00 in a research note on Wednesday, October 1st. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Westpark Capital lifted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, September 30th.

Enanta Pharmaceuticals Stock Down 5.5%

Shares of NASDAQ ENTA opened at $12.61 on Friday. The stock’s fifty day simple moving average is $14.04 and its 200 day simple moving average is $10.68. The stock has a market capitalization of $363.96 million, a price-to-earnings ratio of -3.29 and a beta of 0.95. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. The business had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. As a group, analysts anticipate that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 4,743 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $67,492.89. Following the transaction, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Yat Sun Or sold 2,390 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the completion of the transaction, the insider owned 371,392 shares in the company, valued at approximately $5,284,908.16. This represents a 0.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,961 shares of company stock valued at $170,149 in the last 90 days. 13.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ENTA. Farther Finance Advisors LLC increased its position in Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,779 shares during the last quarter. Quarry LP bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $81,000. Wealth Enhancement Advisory Services LLC acquired a new position in Enanta Pharmaceuticals in the second quarter worth approximately $88,000. China Universal Asset Management Co. Ltd. increased its holdings in Enanta Pharmaceuticals by 103.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after buying an additional 4,454 shares during the last quarter. Finally, AlphaQuest LLC raised its position in Enanta Pharmaceuticals by 18.1% during the third quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 1,562 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.